Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation ...
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCAâ„¢-Lung1, a Phase II clinical ...
Mariadelis Labrador Siles was last seen Monday while wearing a light blue jacket and black Puma shoes with pink soles.
Puma undertakes no obligation to revise or update ... looking at the efficacy of alisertib monotherapy patients with small cell lung cancer. As a reminder, the ALISCA-Breast1 trial investigates ...
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology ... monotherapy for the treatment of patients with extensive stage small cell lung cancer (2025). Revenue Total revenue consists of product ...
Puma reckons that alisertib has potential in ... Aurora kinase A is an enzyme that is involved in cell division and proliferation, and is often overexpressed in cancers. There is evidence that ...
9h
Travel + Leisure on MSNSustainable Travel Innovators: T+L's 2025 Global Vision AwardsThese are the winners of Travel + Leisure's 2025 Global Vision Awards, plus how this year's panel arrived at the final list of 25 honorees.
Siles was last seen Monday, around 9 a.m., while wearing a light blue jacket and black Puma shoes with pink soles ... She left her home without her wallet and cell phone. On Wednesday, the ...
John La Puma, MD, a physician in Santa Barbara ... 3.6 hours per day on their cell phones, laptops, or TV, which turns out to be 46% less than most users who spend an average of 6 hours online ...
Ford CEO Farley says to expect more news this year on its EV investments and strategy. Industry experts suggest that U.S. automakers should have focused on smaller EVs and cheaper battery technology ...
18d
Zacks Investment Research on MSNPBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesPuma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results